CTI Life Sciences / CTI Sciences de la vie
Montreal, QC
Investment Thesis
CTI Life Sciences invests in high-quality emerging life sciences companies at pre-clinical and clinical development stages in Canada and the US, focusing on therapeutic innovation across modalities. The fund operates as a company builder leveraging deep industry expertise to catalyze nascent biotech ideas and assets into investable, scalable platforms with best-in-class therapeutic potential, targeting premium acquisition outcomes from strategic buyers.
Focus Areas
Investment Stage
EarlyGrowthSeed
Sectors
Investment Signals
GeographyNorth America
ProvincesQC
RoleBoth
Revenue Stagepre-revenue ok
Impact MandateYes
Business Modelsdeep-tech, IP-licensing
Sample Portfolio Companies
Ability Pharma
Aeovian Pharmaceuticals
DalCor
enGene
Epitopea
Find Therapeutics
Glycomine
Kainova Therapeutics
Oligon Therapeutics
Thryv Therapeutics
AUM & Sources
Est. C$384M
Assets under management (estimated)
Sources
No public sources found.
Raising from Canadian VCs?Get AI-matched to your top investors in seconds.
Find My Investors →Similar Funds
See incorrect information?
Help us keep this directory accurate and up to date.